Trial Profile

A Phase 1/2 Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of CD19-targeted Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) Therapy in Patients With Relapsed or Refractory B-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PL 001 (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Pell Bio-Med Technology

13 May 2025 Planned End Date changed from 31 Mar 2026 to 31 Mar 2027.
13 May 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.
10 Jan 2024 Planned End Date changed from 24 Sep 2024 to 31 Mar 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com